Total Payments
$536,082
2024 Payments
$93,611
Companies
29
Transactions
503
Medicare Patients
1,329
Medicare Billing
$194,791
Payment Breakdown by Category
Consulting$313,832 (58.5%)
Travel$89,583 (16.7%)
Other$81,120 (15.1%)
Research$38,527 (7.2%)
Food & Beverage$12,164 (2.3%)
Gifts$855.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $313,832 | 105 | 58.5% |
| Travel and Lodging | $89,583 | 140 | 16.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,537 | 31 | 8.9% |
| Unspecified | $38,527 | 21 | 7.2% |
| Honoraria | $23,842 | 11 | 4.4% |
| Food and Beverage | $12,164 | 183 | 2.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,182 | 7 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,475 | 1 | 0.5% |
| Gift | $855.00 | 3 | 0.2% |
| Grant | $84.20 | 1 | 0.0% |
Payments by Type
General
$497,554
482 transactions
Research
$38,527
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $108,384 | 50 | $0 (2024) |
| Amgen Inc. | $86,002 | 95 | $0 (2023) |
| GENZYME CORPORATION | $70,805 | 50 | $0 (2024) |
| Celgene Corporation | $65,626 | 66 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $33,691 | 35 | $0 (2024) |
| GlaxoSmithKline, LLC. | $24,052 | 19 | $0 (2024) |
| Janssen Global Services, LLC | $23,557 | 46 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $17,725 | 11 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $16,708 | 12 | $0 (2017) |
| Janssen Biotech, Inc. | $14,069 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,611 | 74 | Takeda Pharmaceuticals U.S.A., Inc. ($33,544) |
| 2023 | $51,276 | 44 | GENZYME CORPORATION ($21,524) |
| 2022 | $37,247 | 28 | Takeda Pharmaceuticals U.S.A., Inc. ($11,249) |
| 2021 | $39,236 | 23 | Amgen Inc. ($10,378) |
| 2020 | $69,028 | 41 | Amgen Inc. ($14,992) |
| 2019 | $107,086 | 95 | Takeda Pharmaceuticals U.S.A., Inc. ($43,778) |
| 2018 | $70,186 | 117 | Amgen Inc. ($21,067) |
| 2017 | $68,411 | 81 | Celgene Corporation ($16,858) |
All Payment Transactions
503 individual payment records from CMS Open Payments — Page 21 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/27/2017 | Millennium Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $99.00 | General |
| 01/27/2017 | Millennium Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $3.54 | General |
| 01/24/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $124.89 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $14,887 | 4 |
| A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly | Amgen Inc. | $7,626 | 1 |
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $5,211 | 1 |
| B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches | Amgen Inc. | $4,146 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,323 | 2 |
| HEOR | Celgene Corporation | $1,071 | 1 |
| Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (KdD) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) and D-Pd in Relapsed or Refractory Multiple Myeloma | Amgen Inc. | $867.10 | 1 |
| Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (KdD) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) and D-Pd in Relapsed or Refractory Multiple Myeloma | Amgen Inc. | $481.80 | 1 |
| 4170 - CFZ Ph3 CRd (PX-171-009) ASPIRE | Amgen Inc. | $478.32 | 1 |
| Efficacy and safety of weekly carfilzomib (70 mg/m 2), dexamethasone, and daratumumab (KdD70) is co | Amgen Inc. | $462.77 | 1 |
| A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E | GlaxoSmithKline, LLC. | $397.81 | 4 |
| Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials | Amgen Inc. | $388.27 | 1 |
| Efficacy and Safety of Carfilzomib, Dexamethasone, and Daratumumab (KdD) Twice-Weekly at 56 mg/m2 an | Amgen Inc. | $175.14 | 1 |
| P3 Kd v KdD in Relapsed/Refractory MM (CANDOR) | Amgen Inc. | $12.21 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 135 | 143 | $79,513 | $13,241 |
| 2022 | 7 | 382 | 689 | $291,059 | $67,863 |
| 2021 | 8 | 407 | 678 | $266,610 | $68,904 |
| 2020 | 7 | 405 | 578 | $204,370 | $44,783 |
Total Patients
1,329
Total Services
2,088
Medicare Billing
$194,791
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 65 | 71 | $47,557 | $8,037 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 31 | $13,330 | $2,012 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 27 | $10,506 | $1,836 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 14 | $8,120 | $1,356 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 116 | $51,040 | $14,827 | 29.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 126 | $51,660 | $11,897 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 138 | $59,340 | $11,254 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 54 | 90 | $51,789 | $10,745 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 72 | 113 | $35,030 | $9,598 | 27.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 39 | $11,700 | $2,494 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $10,050 | $2,482 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $10,400 | $2,320 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 25 | $7,250 | $1,400 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 14 | $2,800 | $848.84 | 30.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 63 | 105 | $46,200 | $14,706 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 78 | 126 | $39,060 | $11,731 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 120 | $51,600 | $10,552 | 20.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 109 | $44,690 | $10,450 | 23.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 76 | $44,080 | $10,237 | 23.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $14,070 | $3,512 | 25.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 34 | $9,860 | $2,029 | 20.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 26 | 27 | $3,780 | $1,881 | 49.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 27 | $8,100 | $1,803 | 22.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 20 | $4,000 | $1,284 | 32.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 13 | 13 | $1,170 | $718.10 | 61.4% |
About Dr. Ajai Chari, M.D
Dr. Ajai Chari, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376560136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ajai Chari, M.D has received a total of $536,082 in payments from pharmaceutical and medical device companies, with $93,611 received in 2024. These payments were reported across 503 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($313,832).
As a Medicare-enrolled provider, Chari has provided services to 1,329 Medicare beneficiaries, totaling 2,088 services with total Medicare billing of $194,791. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 07/17/2006
- Last Updated 01/21/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1376560136
Products in Payments
- Revlimid (Drug) $58,102
- SARCLISA (Biological) $46,779
- Kyprolis (Biological) $41,098
- DARZALEX (Biological) $33,066
- Kyprolis (Drug) $25,491
- XPOVIO (Drug) $17,725
- IVIG (Biological) $13,231
- CD38 (Drug) $12,155
- NINLARO (Drug) $11,845
- EMPLICITI (Biological) $9,908
- MOZOBIL (Drug) $8,542
- FARYDAK (Drug) $5,825
- Pomalyst (Drug) $5,239
- clonoSEQ (Device) $4,800
- TECVAYLI (Biological) $4,711
- JCAR017 (Drug) $4,000
- Tecartus (Drug) $3,820
- Farydak (Drug) $3,811
- CARVYKTI (Biological) $2,463
- TAZVERIK (Drug) $2,363
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205